Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
Open Access
- 10 June 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 859633
Abstract
Glioblastoma (grade IV glioma) is the most aggressive histopathological subtype of glial tumors with inordinate microvascular proliferation as one of its key pathological features. Extensive angiogenesis in the tumor microenvironment supplies oxygen and nutrients to tumoral cells; retains their survival under hypoxic conditions; and induces an immunosuppressive microenvironment. Anti-angiogenesis therapy for high-grade gliomas has long been studied as an adjuvant immunotherapy strategy to overcome tumor growth. In the current review, we discussed the underlying molecular mechanisms contributing to glioblastoma aberrant angiogenesis. Further, we discussed clinical applications of monoclonal antibodies, tyrosine kinase inhibitors, and aptamers as three major subgroups of anti-angiogenic immunotherapeutics and their limitations. Moreover, we reviewed clinical and preclinical applications of small interfering RNAs (siRNAs) as the next-generation anti-angiogenic therapeutics and summarized their potential advantages and limitations. siRNAs may serve as next-generation anti-angiogenic therapeutics for glioma. Additionally, application of nanoparticles as a delivery vehicle could increase their selectivity and lower their off-target effects.Keywords
This publication has 111 references indexed in Scilit:
- Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma TreatmentMolecular Therapy Nucleic Acids, 2013
- Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cellsExperimental Cell Research, 2012
- Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in ratBiomaterials, 2012
- Phase I trial of sorafenib in patients with recurrent or progressive malignant gliomaNeuro-Oncology, 2011
- Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood–brain barrierNeuroscience, 2011
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium StudyJournal of Clinical Oncology, 2011
- Clinical significance of vasculogenic mimicry in human gliomasJournal of Neuro-Oncology, 2011
- Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine GliomaJournal of Clinical Oncology, 2010
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Neuro-Oncology, 2010
- Stratified phase II trial of cetuximab in patients with recurrent high-grade gliomaAnnals of Oncology, 2009